The Food and Drug Administration today approved a naloxone hydrochloride nasal spray to treat opioid overdoses that delivers 8 milligrams of naloxone, up from 2 mg or 4 mg in previously approved products. 
 
“Addressing the opioid crisis is a top priority for the FDA, and we will continue our efforts to increase access to naloxone and place this important medicine in the hands of those who need it most,” said Patrizia Cavazzoni, M.D., director of FDA’s Center for Drug Evaluation and Research. 
 

Related News Articles

Headline
The Food and Drug Administration Friday revoked its emergency use authorization for Battelle Memorial Institute’s decontamination system for N95…
Headline
The Centers for Medicare & Medicaid Services Friday released a toolkit for qualified health plans applying for plan year 2022 certification, and…
Headline
New information sharing requirements for health information technology take effect April 5 under an interim final rule released last year by the Office of the…
Headline
The Department of Homeland Security yesterday formally removed its public charge rule from the Code of Federal Regulations. The Biden administration this…
Headline
AHA today urged the Department of Health and Human Services’ Office for Civil Rights to take a holistic approach as it deliberates changes to the HIPAA Privacy…
Headline
The Department of Health and Human Services’ Office for Civil Rights today formally published in the Federal Register a proposed rule released Dec. 10 that…